Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to 60.45%.

  • Enanta Pharmaceuticals' EBITDA Margin rose 783700.0% to 60.45% in Q4 2025 from the same period last year, while for Dec 2025 it was 109.08%, marking a year-over-year increase of 566300.0%. This contributed to the annual value of 130.65% for FY2025, which is 492700.0% up from last year.
  • According to the latest figures from Q4 2025, Enanta Pharmaceuticals' EBITDA Margin is 60.45%, which was up 783700.0% from 121.56% recorded in Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' EBITDA Margin peaked at 60.45% during Q4 2025, and registered a low of 221.7% during Q1 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' median EBITDA Margin value was 152.03% (recorded in 2021), while the average stood at 152.93%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by -1045300bps in 2021, then skyrocketed by 828200bps in 2025.
  • Enanta Pharmaceuticals' EBITDA Margin (Quarter) stood at 109.99% in 2021, then dropped by -16bps to 127.25% in 2022, then crashed by -52bps to 193.78% in 2023, then increased by 28bps to 138.82% in 2024, then surged by 56bps to 60.45% in 2025.
  • Its EBITDA Margin was 60.45% in Q4 2025, compared to 121.56% in Q3 2025 and 103.16% in Q2 2025.